DeuteRx is involved in improving medicines for patients. This description is self-described.

DeuteRx

DeuteRx | 254 followers on LinkedIn. Devoted to improving patients&#39; lives and advancing small molecule therapies through Deuterium-Enriched Chiral Switching. | Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. 

DECS is a revolutionary strategy that stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy.

Life Sciences Executive & Serial Entrepreneur

Sheila DeWitt, PhD

Life Sciences CEO | Specializing in Early-stage Companies

Mike Webb

Founder, President, Chairman & CSO at RIFFIT

Lex Van Der Ploeg

Check out the results of our collaborative research effort with POXEL ! #PXL065 is the deuterium-stabilized (R)-enantiomer of pioglitazone and may be a safer and more effective NASH treatment than racemic pioglitazone. #NASH #NonAlcoholicSteatohepatitis #drugdiscovery #drugdevelopment #liverhealth #liverdisease #pioglitazone #DECS #DeuteriumEnabledChiralSwitching #DeuteRx #deuterium #racemic #enantiomer #innovationinhealthcare

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 10:05 PM	c7e1fc15
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 10:05 PM	0770f8e1
crunchbase trigger	general	Nov 9, 2024 10:05 PM	0d8f169a
crunchbase profile	general
li profile	general	Nov 9, 2024 10:05 PM	935bb3ac
translate crunchbase fundingrounds	general
peers	general	Nov 9, 2024 10:05 PM	9b58de31
news basic	general	Nov 9, 2024 10:05 PM	edf6dbee
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

DEUT

COM:DEUTERX

DeuteRx